Published in Diabetes Care on February 19, 2009
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI2D) | NCT00006305
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity. Diabetes Metab Syndr Obes (2011) 1.09
Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling. Cardiovasc Res (2015) 0.77
Flow Cytometric Investigation of Classical and Alternative Platelet Activation Markers. EJIFCC (2013) 0.76
Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl Res (2016) 0.75
Elevated C-reactive protein levels in overweight and obese adults. JAMA (1999) 9.94
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem (1997) 4.77
Platelet activation in obese women: role of inflammation and oxidant stress. JAMA (2002) 2.79
Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med (1990) 2.79
Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation (1991) 2.62
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Blood clotting in minimally altered whole blood. Blood (1996) 2.10
Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest (1974) 1.92
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes (2005) 1.88
Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation (2001) 1.24
Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 1.16
Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation (1995) 1.15
Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol (2006) 1.00
Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes (1985) 1.00
Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res (2006) 0.95
The prevalence, type and severity of cardiovascular disease in diabetic and non-diabetic patients: a matched-paired retrospective analysis using coronary angiography as the diagnostic tool. Mol Cell Biochem (2004) 0.90
Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res (2005) 0.85
Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest (2004) 0.82
Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol (2004) 0.82
Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation (1997) 0.81
Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage. Acta Diabetol Lat (1985) 0.79
Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost (2001) 0.79
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J (2013) 2.79
Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation (2010) 2.64
Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun (2007) 2.35
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2013) 2.15
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81
The temporal variability of dominant frequency and complex fractionated atrial electrograms constrains the validity of sequential mapping in human atrial fibrillation. Heart Rhythm (2010) 1.74
Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest (2004) 1.70
wnt3a but not wnt11 supports self-renewal of embryonic stem cells. Biochem Biophys Res Commun (2006) 1.53
The effect of age on outcomes of coronary artery bypass surgery compared with balloon angioplasty or bare-metal stent implantation among patients with multivessel coronary disease. A collaborative analysis of individual patient data from 10 randomized trials. J Am Coll Cardiol (2012) 1.46
The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload. J Cardiovasc Pharmacol (2013) 1.46
Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol (2009) 1.42
The impact of pharmacologic sympathetic and parasympathetic blockade on atrial electrogram characteristics in patients with atrial fibrillation. Pacing Clin Electrophysiol (2011) 1.42
Morphological and cytochemical determination of cell death by apoptosis. Histochem Cell Biol (2007) 1.42
Coronary disease in type 1 diabetes: causal contiguity and clinical implications. Diabetes Care (2003) 1.38
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc Interv (2009) 1.38
Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 1.37
Improving the utilization of medical crisis teams (Condition C) at an urban tertiary care hospital. J Crit Care (2003) 1.32
Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem (2004) 1.31
TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation (2002) 1.18
Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol (2006) 1.15
Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol (2002) 1.15
TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PLoS One (2009) 1.11
Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol (2003) 1.09
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst (2009) 1.09
Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2012) 1.04
Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg (2007) 1.02
Severity of diabetic foot infection and rate of limb salvage. Foot Ankle Int (2013) 1.02
PAI-1 and diabetes: a journey from the bench to the bedside. Diabetes Care (2012) 0.99
The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost (2008) 0.99
Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation (2002) 0.98
Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol (2009) 0.97
Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol (2003) 0.96
Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis (2002) 0.96
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost (2004) 0.96
Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol (2004) 0.95
The metabolic syndrome: a call to action. Coron Artery Dis (2006) 0.93
A novel dual staining method for identification of apoptotic cells reveals a modest apoptotic response in infarcted mouse myocardium. Histochem Cell Biol (2007) 0.92
Priming with ligands secreted by human stromal progenitor cells promotes grafts of cardiac stem/progenitor cells after myocardial infarction. Stem Cells (2014) 0.92
Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis (2005) 0.91
Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms. Atherosclerosis (2012) 0.91
Endothelial dysfunction and inflammation after percutaneous coronary intervention. Am J Cardiol (2004) 0.90
Emergence of complex behavior: an interactive model of cardiac excitation provides a powerful tool for understanding electric propagation. Circ Arrhythm Electrophysiol (2011) 0.90
Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. Am J Public Health (2010) 0.90
A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart. Exp Biol Med (Maywood) (2009) 0.89
Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev (2012) 0.89
Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial. Diabetes Care (2014) 0.88
Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis (2004) 0.88
Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J Histochem Cytochem (2004) 0.88
Hepatocyte growth factor regulates E box-dependent plasminogen activator inhibitor type 1 gene expression in HepG2 liver cells. Arterioscler Thromb Vasc Biol (2006) 0.87
Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation (2007) 0.86
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. Arterioscler Thromb Vasc Biol (2002) 0.86
The magnitude and temporal dependence of apoptosis early after myocardial ischemia with or without reperfusion. FASEB J (2008) 0.85
Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res (2005) 0.85
Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol (2002) 0.85
Longitudinal effects of weight loss and regain on cytokine concentration of obese adults. Metabolism (2013) 0.85
Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. Int J Cardiol (2006) 0.85
The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol (2011) 0.85
High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. Am J Med Sci (2010) 0.85
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. Coron Artery Dis (2007) 0.84
Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study. Coron Artery Dis (2009) 0.84
Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Prev Cardiol (2010) 0.84
Enhancement by growth factors of cardiac myocyte differentiation from embryonic stem cells: a promising foundation for cardiac regeneration. Biochem Biophys Res Commun (2005) 0.84
Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg (2010) 0.83
IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBPdelta. Am J Physiol Cell Physiol (2006) 0.83
Imaging aspects of cardiovascular disease at the cell and molecular level. Histochem Cell Biol (2008) 0.83
Quality of life after surgical myocardial revascularization, angioplasty or medical treatment. Arq Bras Cardiol (2007) 0.83
The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. J Thorac Cardiovasc Surg (2011) 0.83
Autophagy in myocardium of murine hearts subjected to ischemia followed by reperfusion. Histochem Cell Biol (2010) 0.83
Delineation of the evolution of compositional changes in atheroma. Histochem Cell Biol (2002) 0.82
Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E. J Histochem Cytochem (2005) 0.82
Gap between clinical trials and clinical practice: lessons from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2003) 0.82
Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity (Silver Spring) (2009) 0.82
Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes. Coron Artery Dis (2013) 0.82
Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care (2013) 0.82
Gender-dependent differences in echocardiographic characteristics of murine hearts. Echocardiography (2008) 0.82
Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol (2004) 0.82
Toward a comprehensive approach to pharmacoinvasive therapy for patients with ST segment elevation acute myocardial infarction. J Thromb Thrombolysis (2012) 0.81
Vascular rhexis: loss of integrity of coronary vasculature in mice subjected to myocardial infarction. Exp Biol Med (Maywood) (2010) 0.81
The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry (2009) 0.81
A novel role for tissue-type plasminogen activator: prevention of thromboembolic occlusion. Circulation (2008) 0.81
Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care (2002) 0.81
Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes. Thromb Haemost (2009) 0.81
Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol (2013) 0.80
Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. Histochem Cell Biol (2007) 0.80
Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1). Am J Cardiol (2004) 0.80